Matthew Kaplan

Analyst Matthew Kaplan, carries an average stock price target met ratio of 58.39% that have a potential upside of 73.86% achieved within 239 days. Previously, Matthew Kaplan worked at LADENBURG.

Matthew Kaplan’s has documented 110 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ARDX, Ardelyx at 16-Jun-2026.

Wall Street Analyst Matthew Kaplan

Analyst best performing recommendations are on URGN (UROGEN PHARMA LTD).
The best stock recommendation documented was for URGN (UROGEN PHARMA LTD) at 1/2/2018. The price target of $50 was fulfilled within 20 days with a profit of $11.36 (29.4%) receiving and performance score of 14.7.

Average potential price target upside

• of $44.96 (97.31%) on RETA (REATA PHARMACEUTICALS).
• of $29.43 (16.9%) on UTHR (UNITED THERAPEUTICS).
• of $22.89 (165.61%) on TGTX (TG THERAPEUTICS).